Table 1.
Phase I trials included in the analysis showing the name of the author, year of publication, number of patients enrolled in the trial, the intervention that was tested and the outcome
| Author | Year | No of patients | Intervention | Outcome for CS patients |
|---|---|---|---|---|
| Serrone et al.
[12] |
2001 |
44 advanced sarcoma (2 CS) |
Group A: IFOS short infusion + EPI |
Not mentioned |
| Group B: IFOS continuous infusion + EPI | ||||
| Schwartz et al.
[13] |
2005 |
38 advanced solid tumors with 6 sarcoma with at least 1 CS |
LY293111 (Leucotriene-B4 receptor antagonist) |
1 SD |
| Levine et al.
[14] |
2006 |
51 advanced malignancies with 7 sarcoma with at least 1 CS |
Veglin (VEGF antisense oligodeoxynucleotide) |
1 SD |
| Lockhart et al.
[15] |
2007 |
18 advanced malignancies (1 CS) |
MAC-321 (analogue of docetaxel) |
1 SD |
| Chawla et al.
[16] |
2009 |
20 advanced sarcoma (1 CS) |
Rexin-G (tumor-targeted retrovector) |
Not mentioned |
| Group A: 2 times a week | ||||
| Group B: 3 times a week | ||||
| Camidge et al.
[17] |
2010 |
50 advanced malignancies with 11 sarcoma with at least 1 CS |
PRO95780 (death receptor 5 antibody) |
1 SD |
| Herbst et al.
[18] |
2010 |
71 advanced malignancies with 9 sarcoma with at least 2 CS |
rhApo2L/TRAIL (death receptor activator) |
2 PR |
| Cohort 1: dose escalation | ||||
| Cohort 2: treated at MTD | ||||
| Olmos et al.
[19] |
2010 |
29 advanced sarcoma (1 CS) |
Figitumumab (IGF1R antibody) |
1 SD |
| Qeuk et al.
[20] |
2010 |
21 advanced solid tumors (1 CS) |
Everolimus (mTOR inhibitor) and figitumumab (IGF1R antibody) |
1 SD |
| Stroppa et al.
[21] |
2010 |
8 advanced sarcoma (1 CS) |
Doxorubicin + IFOS |
Not mentioned |
| Pacey et al. [22] | 2011 | 25 advanced solid tumors with at least 1 CS | Alvespimycin (heat shock protein 90 inhibitor) | 1 SD |
CS chondrosarcoma, EPI epirubicin, IFOS ifosfamide, PR partial response, SD stable disease.